News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
<Research>CLSA Envisions JD HEALTH's 1Q25 Rev. & Adj. EBIT to Rise 15% YoY; Rating Kept Outperform
CLSA has released a research report forecasting that JD HEALTH (06618.HK) will deliver solid KPI performance for 1Q25, and that its total revenue will rise by 15% YoY to RMB15.3 bi...
Reset
Send
The window will close in 5 seconds
<Research>CLSA Envisions JD HEALTH's 1Q25 Rev. & Adj. EBIT to Rise 15% YoY; Rating Kept Outperform
Close
Recommend
6
Positive
9
Negative
0
 
SHORT SELL
 
STOCK INFO

CLSA has released a research report forecasting that JD HEALTH (06618.HK)  +1.600 (+4.211%)    Short selling $39.79M; Ratio 14.571%   will deliver solid KPI performance for 1Q25, and that its total revenue will rise by 15% YoY to RMB15.3 billion on increased demand for pharmaceuticals following the flu outbreak since January and improved user traffic on the JD platform thanks to the trade-in subsidy policy.

The broker also predicted JD HEALTH's pharmaceutical sales to leap by 20% YoY during the quarter, while sales of health supplements and medical devices are likely to maintain growth of over 10% YoY. The company's adjusted EBIT is projected to climb by 15% YoY, with the profit margin holding steady at 5.7%.

Related NewsJD HEALTH 1Q Non-IFRS Profit Surges 47.7% YoY
CLSA reiterated an Outperform rating on JD HEALTH and kept its target price at $45.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-05-13 16:25.)

AAStocks Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.